CNR1 and myeloid sarcoma: While CB2R is the major cannabinoid receptor subtype linked with MS pathology, previous studies revealed that CB2R mediated effects are not abolished completely in the presence of receptor-specific antagonists and, importantly, independent of CB1R [443,444].